text: Strategies for drug repurposing against coronavirus targets Repurposing regulatory agency approved drugs and investigational compounds with known safety profiles can significantly fast track the drug development timeline over i de novo i drug discovery with lower investment requirements and improved attrition rate These advantages are vital in any epidemic or pandemic situation where hospital beds are occupied by patients for whom there is no known treatment Here we examine drug repurposing in the context of human coronaviruses SARS CoV MERS CoV and in particular SARS CoV 2 the virus currently causing a continued widespread pandemic with substantial impacts on public health and economy The key druggable targets explored were those involved in viral entry viral replication and viral induced ARDS as well as viral proteases with a focus on the strategy by which the drugs were repurposed 